Navigation Links
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
Date:5/18/2009

SAN FRANCISCO, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

"A significant number of pediatric ADHD patients present with behaviors such as anger, resentfulness, defiance, and arguing with adults. It can be complicated for physicians and caregivers to find the right medication to control symptoms for children with ADHD exhibiting these behaviors," said Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with the primary efficacy results of the current study, these data provide additional support for the clinical efficacy of INTUNIV for treating ADHD in this patient population."

On January 26, 2009, Shire filed a resubmission to the US Food and Drug Administration (FDA) of the New Drug Application to support approval for the treatment of ADHD in children and adolescents. Once available, INTUNIV will be the first selective alpha-2A receptor agonist approved for the treatment of ADHD.

INTUNIV Demonstrated Significant Efficacy in Secondary Endpoints

In this randomized, placebo-controlled, flexible-dose study, INTUNIV demonstrated significant ADHD symptom improvement in patients with oppositional symptoms as measured by the
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
2. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
3. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
6. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
7. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
10. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
11. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
(Date:9/1/2015)... RIVER, Mass. , Sept. 1, 2015   ... an additional 120,000 square feet in Olive Branch, ... Olive Branch facility has added the ... warehousing space. "This expansion gives us the ... Karl Neuberger , President of Millstone MS. "Two and a ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2
(Date:9/1/2015)... ... 2015 , ... According to a study published August 25th in ... in a three year study about weight loss and diabetes were far more likely ... loss surgery at the onset of the trial. In fact, the participants in the ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted ... ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn ... some of whom work for Calvary, and two junior counselors who were campers themselves ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the American Society for Dermatologic Surgery, according to a new survey that ... Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
... 18 (HealthDay News) -- Flu vaccination levels among U.S. ... are still below the 2020 national health objectives, a ... for Disease Control and Prevention also found that too ... care personnel should get an annual flu vaccination, according ...
... tumors aren,t uniform: they are more like complex societies, ... playing different roles. Understanding this "social structure" of tumors ... different cell types may be sensitive to different drugs. ... society, in which all cancer cells descend from special ...
... Fighting Drug, Vemurafenib Powerful X-Rays Enable ... Life-Threatening Diseases WASHINGTON, DC Powerful X-ray ... (DOE,s) national laboratories is revealing new insights into ... and, most recently, enabled the discovery of a ...
... , THURSDAY, Aug. 18 (HealthDay News) -- Many doctors continue ... guidelines say some women can wait much longer between tests. ... Katherine Roland, a behavioral scientist at the U.S. Centers for ... with the guidelines," Roland said. The downsides of too-frequent ...
... For the first time, researchers at Seattle Cancer ... serial positron emission tomography (PET) scans, using a ... of estrogen-blocking and estrogen-depleting therapy in patients with ... are published online in Clinical Cancer Research ...
... , WEDNESDAY, Aug. 17 (HealthDay News) -- A newer ... consciousness while under anesthesia is no better than conventional ... new research shows. In fact, the newer system ... is known as bispectral index (BIS) monitoring -- actually ...
Cached Medicine News:Health News:Flu Shot Rates Low for Health Workers, Moms-to-Be: CDC 2Health News:Cancer stem cells made, not born 2Health News:Cancer stem cells made, not born 3Health News:DOE laboratories help develop promising new cancer fighting drug, vemurafenib 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 3Health News:PET scans confirm effectiveness of estrogen-blocking drugs in breast cancer patients 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 3
... HT is designed for extended temperatures. ... ideal for applications such as DNA ... Incubator/Shaker HT is available as a ... three microplates. Iems Incubator/Shaker HT including ...
... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer for any kind of cell ... CyFlow SL analyzes forward and side ... to 3 fluorescence channels. Data acquisition, ... with a PC or laptop employing ...
Medicine Products: